Genscript Biotech (FRA:G51) Ending Cash Position : €126.1 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Genscript Biotech Ending Cash Position?

Genscript Biotech's Ending Cash Position for the quarter that ended in Dec. 2024 was €126.1 Mil.

Genscript Biotech's quarterly Ending Cash Position declined from Dec. 2023 (€1,326.4 Mil) to Jun. 2024 (€370.9 Mil) and declined from Jun. 2024 (€370.9 Mil) to Dec. 2024 (€126.1 Mil).

Genscript Biotech's annual Ending Cash Position increased from Dec. 2022 (€966.7 Mil) to Dec. 2023 (€1,326.4 Mil) but then declined from Dec. 2023 (€1,326.4 Mil) to Dec. 2024 (€126.1 Mil).

Genscript Biotech Ending Cash Position Historical Data

The historical data trend for Genscript Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Ending Cash Position Chart

Genscript Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

517.09

1,045.16

966.66

1,326.35

126.05

Genscript Biotech Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															966.66	1,289.74	1,326.35	370.95	126.05

Genscript Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Genscript Biotech's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1381.314	+	-1255.264
	=	126.1

Genscript Biotech's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	381.329	+	-255.279
	=	126.1

Genscript Biotech Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (FRA:G51) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

GNNSF:USA 01548:Hong Kong G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

Genscript Biotech Corp is a China-based provider of life science research services and products. The firm is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. The company's business segments include Life-science services and products, Biologics development services, Industrial synthetic biology products, and the Operation unit. The company generates the majority of its revenue from the life-science services and products unit, which provides comprehensive research services and products, which are widely used and are fundamental to life-science research and application. Geographically, the company generates the majority of its revenue from the United States of America, followed by Mainland China.

Genscript Biotech Headlines

No Headlines